Comments on concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a mist of mysterious results.
Publication
, Journal Article
Cheng, SH; Huang, AT
Published in: J Clin Oncol
April 20, 2005
Duke Scholars
Published In
J Clin Oncol
DOI
ISSN
0732-183X
Publication Date
April 20, 2005
Volume
23
Issue
12
Start / End Page
2864 / 2865
Location
United States
Related Subject Headings
- Reproducibility of Results
- Prognosis
- Patient Selection
- Oncology & Carcinogenesis
- Neoplasm Staging
- Neoplasm Metastasis
- Nasopharyngeal Neoplasms
- Humans
- Endpoint Determination
- Clinical Trials, Phase III as Topic
Citation
APA
Chicago
ICMJE
MLA
NLM
Cheng, S. H., & Huang, A. T. (2005). Comments on concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a mist of mysterious results. J Clin Oncol, 23(12), 2864–2865. https://doi.org/10.1200/JCO.2005.05.146
Cheng, Skye H., and Andrew T. Huang. “Comments on concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a mist of mysterious results.” J Clin Oncol 23, no. 12 (April 20, 2005): 2864–65. https://doi.org/10.1200/JCO.2005.05.146.
Cheng SH, Huang AT. Comments on concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a mist of mysterious results. J Clin Oncol. 2005 Apr 20;23(12):2864–5.
Cheng, Skye H., and Andrew T. Huang. “Comments on concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a mist of mysterious results.” J Clin Oncol, vol. 23, no. 12, Apr. 2005, pp. 2864–65. Pubmed, doi:10.1200/JCO.2005.05.146.
Cheng SH, Huang AT. Comments on concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a mist of mysterious results. J Clin Oncol. 2005 Apr 20;23(12):2864–2865.
Published In
J Clin Oncol
DOI
ISSN
0732-183X
Publication Date
April 20, 2005
Volume
23
Issue
12
Start / End Page
2864 / 2865
Location
United States
Related Subject Headings
- Reproducibility of Results
- Prognosis
- Patient Selection
- Oncology & Carcinogenesis
- Neoplasm Staging
- Neoplasm Metastasis
- Nasopharyngeal Neoplasms
- Humans
- Endpoint Determination
- Clinical Trials, Phase III as Topic